Figure 2.

Patients with high plasma cfDNA levels show significantly lower ORR and shorter PFS and OS than those with low cfDNA levels. The baseline cfDNA level was quantified for 85 u-HCC patients treated with Atezo/Bev. The patients were classified into two groups according to the median value of plasma cfDNA level. (A,B) The best overall response rate (ORR) (A) and disease control rate (DCR) (B) in each group. (C,D) The Kaplan–Meier curves of progression-free survival (PFS) (C) and overall survival (OS) (D) for each group. cfDNA, cell-free DNA; u-HCC, unresectable hepatocellular carcinoma; Atezo/Bev, Atezolizumab and bevacizumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.